Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply

Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides drug substance as fast as 13 months at competitive prices. The novel program is called ‘Lean-to-Clinic’ and leverages Boehringer Ingelheim’s established platforms and processes for the production of monoclonal antibodies using the proprietary BI-HEX® high expression system.

The improved approach combines Boehringer Ingelheim’s automated high throughput technologies in process science with a lean drug development approach to offer cost-effective services with shorter timelines. Within the Boehringer Ingelheim “one-stop-shop” service drug substances for toxicological and clinical studies may be delivered after only 13 months and drug products for clinical studies already after 16 months.

“‘Lean to Clinic’ is another milestone of our winning offers strategy to secure technology leadership, flexibility and customer orientation”, commented Simon Sturge, Corporate Senior Vice President Biopharmaceuticals at Boehringer Ingelheim. “‘Lean to Clinic’ consists of streamlined work packages and significantly speeds up cell line development, phase I process development and preclinical and clinical supplies from mammalian cell cultures.”